Brett R. Hagen, the Chief Accounting Officer of Allovir, Inc. (NASDAQ:ALVR), a company with a market capitalization of $49.2 ...

Miller Edward, General Counsel at Allovir, Inc. (NASDAQ:ALVR), recently sold shares of the company's common stock, according to a filing with the Securities and Exchange Commission. The transactions, ...

EST AlloVir (ALVR) trading halted, news pendingStay Ahead of the Market:Discover outperforming stocks and invest smarter with Top Smart ...

Monteverde & Associates PC (the 'M&A Class Action Firm'), has recovered millions of dollars for shareholders and is ...

After Kalaris and AlloVir combine, the new company will have about $100 million to advance a treatment for age-related macular degeneration. As the U.S. stock market navigates a landscape shaped ...

In a recent development, AlloVir, Inc. (NASDAQ:ALVR), a company specializing in biological products currently trading at $0.45 per share, received approval from its shareholders for a reverse ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

AlloVir, Inc. (NASDAQ:ALVR), a biotechnology company specializing in biological products, announced today that it has completed a reverse stock split of its common stock at a 1-for-23 ratio. The move ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

In a recent development, AlloVir, Inc. (NASDAQ:ALVR), a company specializing in biological products currently trading at $0.45 per share, received approval from its shareholders for a reverse stock ...

Enhance your stock picks with dividend metrics like per-share dividends, yield, frequency, payout ratios, and more.